24581-99-5 Usage
General Description
AKOS B028939, also known as 2-Buten-1-ol, is a chemical compound with the molecular formula C4H8O. It is a colorless liquid with a sharp, fruity odor that is commonly used as a solvent, intermediate, and fragrance ingredient in various industrial and consumer products. AKOS B028939 has a wide range of applications, including as a precursor in the production of pharmaceuticals, pesticides, and plastics. It is also used as a flavoring agent and fragrance in the food and beverage, cosmetic, and personal care industries. Additionally, it can be found in cleaning products and as a solvent in laboratory processes. When handling AKOS B028939, it is important to follow proper safety precautions due to its flammable and potentially hazardous nature.
Check Digit Verification of cas no
The CAS Registry Mumber 24581-99-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,5,8 and 1 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 24581-99:
(7*2)+(6*4)+(5*5)+(4*8)+(3*1)+(2*9)+(1*9)=125
125 % 10 = 5
So 24581-99-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H9BrO4/c1-14-10(13)6-15-9-3-2-8(11)4-7(9)5-12/h2-5H,6H2,1H3
24581-99-5Relevant articles and documents
Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists
Sall, Daniel J.,Arfsten, Ann E.,Bastian, Jolie A.,Denney, Michael L.,Harms, Cathy S.,McCowan, Jefferson R.,Morin Jr., John M.,Rose, Jack W.,Scarborough, Robert M.,Smyth, Mark S.,Um, Suzane L.,Utterback, Barbara G.,Vasileff, Robert T.,Wikel, James H.,Wyss, Virginia L.,Jakubowski, Joseph A.
, p. 2843 - 2857 (2007/10/03)
The use of 5,6-bicyclic amidines as arginine surrogates in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) antagonists is described. The additional conformational restriction offered by the bicyclic nucleus results in 20-400-fold increases in potency compared to the freely flexible, acyclic benzamidine counterpart. The design, synthesis, structure-activity relationships (SAR), and in vitro activity of this novel class of GPIIb-IIIa antagonists are presented.
